{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:49:38Z","timestamp":1787222978552,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Genetic Engineering and Biotechnology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1186\/s43141-022-00353-0","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T06:02:39Z","timestamp":1653372159000},"page":"78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives"],"prefix":"10.1016","volume":"20","author":[{"given":"Abas","family":"Sezer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervisa","family":"Halilovi\u0107-Alihod\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annissa Rachel","family":"Vanwieren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adna","family":"Smajkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Kari\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husein","family":"Djedovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-6908","authenticated-orcid":false,"given":"Jasmin","family":"\u0160utkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s43141-022-00353-0_bib1","unstructured":"Cascella M, Rajnik M, Aleem A, Dulebohn S, Napoli R (2021) Features, evaluation, and treatment of coronavirus (COVID-19). 10.23812\/21-3-E, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/. Retrieved 28 Dec 2021"},{"key":"10.1186\/s43141-022-00353-0_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tifs.2020.06.007","article-title":"COVID-19 outbreak: What should be done to avoid food shortages?","volume":"102","author":"de Paulo Farias","year":"2020","journal-title":"Trends Food Sci Technol"},{"key":"10.1186\/s43141-022-00353-0_bib3","doi-asserted-by":"crossref","unstructured":"Ahmad S (2020) A review of COVID-19 (Coronavirus Disease-2019) Diagnosis, treatments and prevention. Eurasian J Med Oncol. https:\/\/doi.org\/10.14744\/ejmo.2020.90853","DOI":"10.14744\/ejmo.2020.90853"},{"key":"10.1186\/s43141-022-00353-0_bib4","unstructured":"Khadka S., Yuchi A., Shrestha DB., Budhathoki P., Al-Subari SMM., Ziad Alhouzani TM., Anwar Butt I (2020) Repurposing drugs for covid-19: an approach for treatment in the pandemic. Alternative therapies in health medicine. Retrieved December 28, 2021, from https:\/\/pubmed.ncbi.nlm.nih.gov\/32827400\/"},{"key":"10.1186\/s43141-022-00353-0_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107930","article-title":"Drug repurposing for COVID-19: Approaches, challenges and promising candidates","volume":"228","author":"Ng","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1186\/s43141-022-00353-0_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2021.103696","article-title":"Drug repurposing for COVID-19 via knowledge graph completion","volume":"115","author":"Zhang","year":"2021","journal-title":"J Biomed Inform"},{"issue":"2","key":"10.1186\/s43141-022-00353-0_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/bib\/bbaa288","article-title":"A review on drug repurposing applicable to COVID-19","volume":"22","author":"Dotolo","year":"2021","journal-title":"Brief Bioinform"},{"issue":"08","key":"10.1186\/s43141-022-00353-0_bib8","first-page":"157","article-title":"Drug repositioning: concept, classification, methodology, and importance in rare\/orphans and neglected diseases","volume":"8","author":"de Oliveira","year":"2018","journal-title":"J Appl Pharm Sci"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"issue":"7","key":"10.1186\/s43141-022-00353-0_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1186\/s43141-022-00353-0_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/13543776.2021.1861248","article-title":"Repurposing drugs for the management of COVID-19","volume":"31","author":"Cusinato","year":"2021","journal-title":"Expert Opin Ther Patents"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1186\/s43141-022-00353-0_bib13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug repurposing approach to fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol Rep"},{"key":"10.1186\/s43141-022-00353-0_bib14","doi-asserted-by":"crossref","unstructured":"Parvathaneni V, Gupta V (2020) Utilizing drug repurposing against COVID-19\u2013Efficacy, limitations, and challenges. Life Sci:118275. https:\/\/doi.org\/10.1016\/j.lfs.2020.118275","DOI":"10.1016\/j.lfs.2020.118275"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci Trends"},{"issue":"11","key":"10.1186\/s43141-022-00353-0_bib16","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1093\/bioinformatics\/btaa224","article-title":"Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus","volume":"36","author":"Liu","year":"2020","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1186\/s43141-022-00353-0_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101303","article-title":"Current status of COVID-19 therapies and drug repositioning applications","volume":"23","author":"Altay","year":"2020","journal-title":"Iscience"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43588-020-00007-6","article-title":"Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies","volume":"1","author":"Galindez","year":"2021","journal-title":"Nat Comput Sci"},{"issue":"10","key":"10.1186\/s43141-022-00353-0_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature","volume":"41","author":"Chatre","year":"2018","journal-title":"Drug Saf"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06595-6","article-title":"Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir\/ritonavir plus interferon alfa-2b against SARS-CoV-2","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"issue":"4","key":"10.1186\/s43141-022-00353-0_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5483\/BMBRep.2020.53.4.080","article-title":"COVID-19: an update on diagnostic and therapeutic approaches","volume":"53","author":"Iyer","year":"2020","journal-title":"BMB Rep"},{"key":"10.1186\/s43141-022-00353-0_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/TCRM.S301817","article-title":"Chloroquine and hydroxychloroquine for the prevention and treatment of COVID-19: a fiction, hope or hype? An updated review","volume":"17","author":"Saghir","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1186\/s43141-022-00353-0_bib25","article-title":"Side effects of chloroquine and primaquine and symptom reduction in malaria endemic area (M\u00e2ncio Lima, Acre, Brazil)","volume":"2015","author":"Braga","year":"2015","journal-title":"Interdisciplin Perspect Infect Dis"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22207\/JPAM.15.1.35","article-title":"Repurposing of the herbals as immune-boosters in the prevention and management of COVID-19: a review","volume":"15","author":"Kumari","year":"2021","journal-title":"J Pure Appl Microbiol"},{"issue":"6","key":"10.1186\/s43141-022-00353-0_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","volume":"26","author":"Chorin","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1186\/s43141-022-00353-0_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1186\/s43141-022-00353-0_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy \u2014 implications of research advances for rheumatology care","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1186\/s43141-022-00353-0_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003252","article-title":"COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology","volume":"17","author":"White","year":"2020","journal-title":"PLoS Med"},{"issue":"3","key":"10.1186\/s43141-022-00353-0_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dsx.2020.03.011","article-title":"Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1186\/s43141-022-00353-0_bib32","doi-asserted-by":"crossref","unstructured":"Dagens A, Sigfrid L, Cai E, Lipworth S, Cheng V, Harris E, Bannister P, Rigby I, Horby P (2020) Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ:m1936. https:\/\/doi.org\/10.1136\/bmj.m1936","DOI":"10.1136\/bmj.m1936"},{"key":"10.1186\/s43141-022-00353-0_bib33","unstructured":"Stokkermans TJ, Goyal A, Bansal P, Trichonas G (2021) Chloroquine and hydroxychloroquine toxicity. StatPearls Publishing, Treasure Island"},{"issue":"6","key":"10.1186\/s43141-022-00353-0_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41397-021-00242-8","article-title":"G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine\/hydroxychloroquine based treatments for COVID-19","volume":"21","author":"da Rocha","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"10.1186\/s43141-022-00353-0_bib35","doi-asserted-by":"crossref","unstructured":"de Siqueira Carvalho AA (2020) Side effects of chloroquine and hydroxychloroquine on skeletal muscle: a narrative review. Curr Pharmacol Rep:1\u20139. https:\/\/doi.org\/10.1007\/s40495-020-00243-4","DOI":"10.1007\/s40495-020-00243-4"},{"issue":"5","key":"10.1186\/s43141-022-00353-0_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2020.102640","article-title":"Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature","volume":"42","author":"de Luca","year":"2021","journal-title":"Am J Otolaryngol"},{"key":"10.1186\/s43141-022-00353-0_bib37","doi-asserted-by":"crossref","unstructured":"Senanayake SL (2020) Drug repurposing strategies for COVID-19. Future. Drug Des Discov 2(2). https:\/\/doi.org\/10.4155\/fdd-2020-0010","DOI":"10.4155\/fdd-2020-0010"},{"issue":"3","key":"10.1186\/s43141-022-00353-0_bib38","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1097\/MJT.0000000000001377","article-title":"Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19","volume":"28","author":"Kory","year":"2021","journal-title":"Am J Ther"},{"key":"10.1186\/s43141-022-00353-0_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir Res"},{"key":"10.1186\/s43141-022-00353-0_bib40","doi-asserted-by":"crossref","unstructured":"H\u00e9ctor C, Roberto H, Psaltis A, Veronica C (2020) Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. J Biomed Res Clin Investig 2(1). https:\/\/doi.org\/10.31546\/2633-8653.1007","DOI":"10.31546\/2633-8653.1007"},{"key":"10.1186\/s43141-022-00353-0_bib41","doi-asserted-by":"crossref","unstructured":"Shoumann WM, Hegazy AA, Nafae RM, Ragab MI, Samra SR, Ibrahim DA et al (2021) Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomized clinical trial. J Clin Diagn Res 15(2). https:\/\/doi.org\/10.7860\/JCDR\/2021\/46795.14529","DOI":"10.7860\/JCDR\/2021\/46795.14529"},{"key":"10.1186\/s43141-022-00353-0_bib42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","article-title":"A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness","volume":"103","author":"Ahmed","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun Biol"},{"issue":"3","key":"10.1186\/s43141-022-00353-0_bib44","first-page":"325","article-title":"Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications","volume":"15","author":"Kircik","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"9070","key":"10.1186\/s43141-022-00353-0_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"Gardon","year":"1997","journal-title":"Lancet"},{"issue":"8","key":"10.1186\/s43141-022-00353-0_bib46","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.trstmh.2006.02.003","article-title":"First case of ivermectin-induced severe hepatitis","volume":"100","author":"Veit","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1186\/s43141-022-00353-0_bib47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin\u2014do they occur beyond the indication of onchocerciasis?","volume":"98","author":"Chandler","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"10.1186\/s43141-022-00353-0_bib48","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3390\/pharmaceutics13101533","article-title":"Forms and methods for interferon\u2019s encapsulation","volume":"13","author":"Ramos","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.17269\/s41997-021-00473-z","article-title":"Risk society and COVID-19","volume":"112","author":"Fardin","year":"2021","journal-title":"Can J Public Health"},{"issue":"7","key":"10.1186\/s43141-022-00353-0_bib50","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1086\/382597","article-title":"Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha","volume":"189","author":"Str\u00f6her","year":"2004","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12879-016-1492-4","article-title":"Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia","volume":"16","author":"Al Ghamdi","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1186\/s43141-022-00353-0_bib52","doi-asserted-by":"crossref","unstructured":"Nakhlband, A., Fakhari, A., & Azizi, H. (2021) Interferon-alpha position in combating with COVID-19: a systematic review. J Med Virol, 93(9), 5277\u20135284. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/jmv.27072","DOI":"10.1002\/jmv.27072"},{"key":"10.1186\/s43141-022-00353-0_bib53","article-title":"Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study","author":"Wang","year":"2020","journal-title":"Research Square"},{"issue":"6515","key":"10.1186\/s43141-022-00353-0_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"4\u20135","key":"10.1186\/s43141-022-00353-0_bib55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.micinf.2020.05.012","article-title":"Arbidol\/IFN-\u03b12b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study","volume":"22","author":"Xu","year":"2020","journal-title":"Microbes Infect"},{"key":"10.1186\/s43141-022-00353-0_bib56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3389\/fphar.2020.01071","volume":"11","author":"Huang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1186\/s43141-022-00353-0_bib57","doi-asserted-by":"crossref","unstructured":"Hashimoto Y, Suzuki T, Hashimoto K (2022) Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry:1\u201310. https:\/\/doi.org\/10.1038\/s41380-021-01432-3","DOI":"10.1038\/s41380-021-01432-3"},{"issue":"22","key":"10.1186\/s43141-022-00353-0_bib58","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib59","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized, platform clinical trial","volume":"10","author":"Reis","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"11","key":"10.1186\/s43141-022-00353-0_bib60","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1093\/cid\/ciaa1492","article-title":"Fecal microbiota transplantation: tales of caution","volume":"72","author":"Khanna","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1186\/s43141-022-00353-0_bib61","doi-asserted-by":"crossref","unstructured":"Hashimoto Y, Suzuki T, Hashimoto K (2021) Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci:1\u20133","DOI":"10.1007\/s00406-021-01326-z"},{"issue":"3","key":"10.1186\/s43141-022-00353-0_bib62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0890334415582207","article-title":"Gastrointestinal side effects in the baby of a breastfeeding woman treated with low-dose fluvoxamine","volume":"31","author":"Uguz","year":"2015","journal-title":"J Hum Lact"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.909","article-title":"Molnupiravir: a new candidate for COVID-19 treatment","volume":"10","author":"Pourkarim","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"628","key":"10.1186\/s43141-022-00353-0_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1186\/s43141-022-00353-0_bib65","doi-asserted-by":"crossref","unstructured":"Zarenezhad E, Marzi M (2022) Review on molnupiravir as a promising oral drug for the treatment of COVID-19. Med Chem Res:1\u201312. https:\/\/doi.org\/10.1007\/s00044-021-02841-3","DOI":"10.1007\/s00044-021-02841-3"},{"issue":"6","key":"10.1186\/s43141-022-00353-0_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"10.1186\/s43141-022-00353-0_bib67","article-title":"RdRp inhibitors and COVID-19: is molnupiravir a good option?","volume":"146","author":"Hashemian","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1186\/s43141-022-00353-0_bib68","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1093\/jac\/dkaa331","article-title":"The impact of sofosbuvir\/daclatasvir or ribavirin in patients with severe COVID-19","volume":"75","author":"Eslami","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1186\/s43141-022-00353-0_bib69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jac\/dkaa501","article-title":"Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial","volume":"76","author":"Roozbeh","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1186\/s43141-022-00353-0_bib70","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.jinf.2020.12.021","article-title":"Sofosbuvir\/daclatasvir in the treatment of COVID-19 infection: a meta-analysis","volume":"82","author":"Chan","year":"2021","journal-title":"J Infect"},{"key":"10.1186\/s43141-022-00353-0_bib71","first-page":"1091A","article-title":"No Resistance Detected in four Phase 3 Clinical Studies in HCV Genotype 1-6 of Sofosbuvir plus Ribavirin with or without Peginterferon","volume":"58","author":"Svarovskaia","year":"2013","journal-title":"Hepatology"},{"key":"10.1186\/s43141-022-00353-0_bib72","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.18006\/2020.8(Spl-1-SARS-CoV-2).S210.S218","article-title":"COVID-19 vaccine acceptance: beliefs and barriers associated with vaccination among the general population in India","volume":"8","author":"Sharun","year":"2020","journal-title":"J Exp Biol Agric Sci"},{"key":"10.1186\/s43141-022-00353-0_bib73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2020.06.032","article-title":"Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections","volume":"156","author":"Sies","year":"2020","journal-title":"Free Radic Biol Med"},{"issue":"10098","key":"10.1186\/s43141-022-00353-0_bib74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(17)31791-9","article-title":"Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"390","author":"Kil","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1186\/s43141-022-00353-0_bib75","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/npp.2015.343","article-title":"Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans","volume":"41","author":"Singh","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"7811","key":"10.1186\/s43141-022-00353-0_bib76","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M pro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"14","key":"10.1186\/s43141-022-00353-0_bib77","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s00213-016-4319-5","article-title":"Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing","volume":"233","author":"Masaki","year":"2016","journal-title":"Psychopharmacology"},{"issue":"10236","key":"10.1186\/s43141-022-00353-0_bib78","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1186\/s43141-022-00353-0_bib79","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3389\/fphar.2020.572870","article-title":"Potential therapeutic options for COVID-19: current status, challenges, and future perspectives","volume":"11","author":"Sarkar","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1186\/s43141-022-00353-0_bib80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1186\/s43141-022-00353-0_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112517","article-title":"RdRp inhibitors and COVID-19: is molnupiravir a good option?","volume":"146","author":"Hashemian","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1186\/s43141-022-00353-0_bib82","doi-asserted-by":"crossref","unstructured":"Alam S, Kamal TB, Sarker MMR, Zhou JR, Rahman SA, Mohamed IN (2021) Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.659577","DOI":"10.3389\/fphar.2021.659577"},{"key":"10.1186\/s43141-022-00353-0_bib83","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.2147\/IJGM.S332458","article-title":"Effectiveness of remdesivir, lopinavir\/ritonavir, and favipiravir for COVID-19 treatment: a systematic review","volume":"14","author":"Qomara","year":"2021","journal-title":"Int J Gen Med"},{"issue":"2","key":"10.1186\/s43141-022-00353-0_bib84","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40495-021-00253-w","article-title":"Efficacy and safety of new and emerging drugs for COVID-19: Favipiravir and Dexamethasone","volume":"7","author":"Sood","year":"2021","journal-title":"Curr Pharmacol Rep"},{"key":"10.1186\/s43141-022-00353-0_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.604447","article-title":"Emerging therapeutic approaches to combat COVID-19: present status and future perspectives","volume":"8","author":"Vivekanandhan","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"6","key":"10.1186\/s43141-022-00353-0_bib86","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jiac.2021.02.018","article-title":"A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19","volume":"27","author":"Gong","year":"2021","journal-title":"J Infect Chemother"},{"issue":"11","key":"10.1186\/s43141-022-00353-0_bib87","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/jac\/dkaa332","article-title":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","volume":"75","author":"Abbaspour Kasgari","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1186\/s43141-022-00353-0_bib88","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1098612X19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J Feline Med Surg"},{"issue":"10043","key":"10.1186\/s43141-022-00353-0_bib89","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1186\/s43141-022-00353-0_bib91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cegh.2020.07.011","article-title":"Remdesivir and its antiviral activity against COVID-19: a systematic review","volume":"9","author":"Frediansyah","year":"2021","journal-title":"Clin Epidemiol Global Health"},{"key":"10.1186\/s43141-022-00353-0_bib92","doi-asserted-by":"crossref","unstructured":"Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2001191","DOI":"10.1056\/NEJMoa2001191"},{"key":"10.1186\/s43141-022-00353-0_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173926","article-title":"Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis","volume":"897","author":"Rezagholizadeh","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1186\/s43141-022-00353-0_bib94","unstructured":"WHO. (2020). \u201cSolidarity\u201d clinical trial for COVID-19 treatments."},{"issue":"4","key":"10.1186\/s43141-022-00353-0_bib95","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jtcme.2020.05.004","article-title":"Dietary therapy and herbal medicine for COVID-19 prevention: a review and perspective","volume":"10","author":"Panyod","year":"2020","journal-title":"J Tradit Complement Med"},{"issue":"3","key":"10.1186\/s43141-022-00353-0_bib96","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40495-020-00216-7","article-title":"An update on current therapeutic drugs treating COVID-19","volume":"6","author":"Wu","year":"2020","journal-title":"Curr Pharmacol Rep"},{"issue":"01","key":"10.1186\/s43141-022-00353-0_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.47419\/bjbabs.v2i01.25","article-title":"Herbal medicine as an alternative method to treat and prevent COVID-19","volume":"2","author":"Al-Doori","year":"2021","journal-title":"Baghdad J Biochem Appl Biol Sci"},{"issue":"4","key":"10.1186\/s43141-022-00353-0_bib98","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.joim.2020.04.001","article-title":"Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine","volume":"18","author":"Wang","year":"2020","journal-title":"J Integr Med"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12011-021-02623-3","article-title":"The role of diet and supplementation of natural products in COVID-19 prevention","volume":"200","author":"Gasmi","year":"2022","journal-title":"Biol Trace Elem Res"},{"key":"10.1186\/s43141-022-00353-0_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153337","article-title":"Traditional Chinese herbal medicine at the forefront battle against COVID-19: clinical experience and scientific basis","volume":"80","author":"Lee","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1186\/s43141-022-00353-0_bib101","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1016\/j.csbj.2020.11.010","article-title":"Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor","volume":"18","author":"Pan","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1186\/s43141-022-00353-0_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153279","article-title":"Contribution of traditional Chinese medicine to the treatment of COVID-19","volume":"85","author":"Wang","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1186\/s43141-022-00353-0_bib103","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1186\/s12879-021-06457-1","article-title":"Associations of immunological features with COVID-19 severity: a systematic review and meta-analysis","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1186\/s43141-022-00353-0_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110641","article-title":"Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: advances and prospects","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1186\/s43141-022-00353-0_bib105","first-page":"1","article-title":"Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the neutrophil\/lymphocyte ratio and plasma levels of IL-6 and IFN\u03b1: an open-label, single-arm pilot study","volume":"4","author":"Kageyama","year":"2022","journal-title":"World Acad Sci J"},{"issue":"10","key":"10.1186\/s43141-022-00353-0_bib106","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2174\/138920011798062328","article-title":"Toxicities by herbal medicines with emphasis to traditional Chinese medicine","volume":"12","author":"Efferth","year":"2011","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1186\/s43141-022-00353-0_bib107","doi-asserted-by":"crossref","first-page":"128","DOI":"10.18773\/austprescr.2003.095","article-title":"The quality and safety of traditional traditional Chinese medicines","volume":"26","author":"Li","year":"2003","journal-title":"Aust Prescr"}],"container-title":["Journal of Genetic Engineering and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43141-022-00353-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43141-022-00353-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X23008776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X23008776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43141-022-00353-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:59:22Z","timestamp":1761659962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687157X23008776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1687157X23008776"],"URL":"https:\/\/doi.org\/10.1186\/s43141-022-00353-0","relation":{},"ISSN":["1687-157X"],"issn-type":[{"value":"1687-157X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives","name":"articletitle","label":"Article Title"},{"value":"Journal of Genetic Engineering and Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s43141-022-00353-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Academy of Scientific Research and Technology. Published by Elsevier BV.","name":"copyright","label":"Copyright"}],"article-number":"78"}}